Squamous cell carcinoma - Сквамозни Карцином
☆ У резултатима Стифтунг Варентест-а за 2022. из Немачке, задовољство потрошача МоделДерм-ом је само нешто ниже него са плаћеним телемедицинским консултацијама.
Squamous cell carcinoma well differentiated ― Примећена је суседна актинична кератоза.
References
Squamous cell carcinoma (SCC) је други најчешћи рак коже у Сједињеним Државама, после basal cell carcinoma. Обично почиње од преканцерозних лезија званих actinic keratosis и може се проширити на друге делове тела. Главни узрок је излагање ултраљубичастом (УВ) зрачењу сунца, које се акумулира током времена. Лечење обично укључује хируршко уклањање, посебно за СЦЦ на глави и врату. Радиотерапија је опција за старије пацијенте или оне који не могу да имају операцију. Имуносупресија повећава ризик од СЦЦ. Иако ретко, СЦЦ се може ширити, посебно код пацијената са ослабљеним имунолошким системом. Редовни прегледи и заштита од сунца важни су за оне са СЦЦ.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) је други најчешћи рак код људи, а његов број расте. Иако ЦСЦЦ обично показује бенигно клиничко понашање, може се ширити и локално и на друге делове тела. Научници су идентификовали специфичне путеве укључене у развој ЦСЦЦ-а, што је довело до нових третмана. Велики број мутација и повећан ризик код имуносупресивних пацијената подстакли су развој имунотерапије. Овај преглед разматра генетске корене ЦСЦЦ-а и најновије третмане који циљају специфичне молекуле и имуни систем.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Дијагноза и лечење
#Dermoscopy
#Skin biopsy